252 related articles for article (PubMed ID: 38003995)
1. Tolerated Re-Challenge of Immunotherapy in a Patient with ICI Associated Myocarditis: A Case Report and Literature Review.
Shalata W; Attal ZG; Shhadi R; Abu Salman A; Abu Jama A; Shalata S; Halumi K; Yakobson A
Medicina (Kaunas); 2023 Nov; 59(11):. PubMed ID: 38003995
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitor-Associated Myocarditis.
Ganatra S; Neilan TG
Oncologist; 2018 Aug; 23(8):879-886. PubMed ID: 29802219
[TBL] [Abstract][Full Text] [Related]
3. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Wang DY; Salem JE; Cohen JV; Chandra S; Menzer C; Ye F; Zhao S; Das S; Beckermann KE; Ha L; Rathmell WK; Ancell KK; Balko JM; Bowman C; Davis EJ; Chism DD; Horn L; Long GV; Carlino MS; Lebrun-Vignes B; Eroglu Z; Hassel JC; Menzies AM; Sosman JA; Sullivan RJ; Moslehi JJ; Johnson DB
JAMA Oncol; 2018 Dec; 4(12):1721-1728. PubMed ID: 30242316
[TBL] [Abstract][Full Text] [Related]
4. Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action.
Neilan TG; Rothenberg ML; Amiri-Kordestani L; Sullivan RJ; Steingart RM; Gregory W; Hariharan S; Hammad TA; Lindenfeld J; Murphy MJ; Moslehi JJ;
Oncologist; 2018 Aug; 23(8):874-878. PubMed ID: 29802220
[TBL] [Abstract][Full Text] [Related]
5. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
Boutros A; Bottini A; Rossi G; Tanda ET; Spagnolo F; Barletta G; Croce E; Fava P; Parisi A; De Rosa F; Palla M; Marconcini R; Ferrari M; Grandis M; Spallarossa P; Sarocchi M; Arboscello E; Del Mastro L; Lambertini M; Pronzato P; Genova C
ESMO Open; 2023 Feb; 8(1):100791. PubMed ID: 36791639
[TBL] [Abstract][Full Text] [Related]
6. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.
Hamada N; Maeda A; Takase-Minegishi K; Kirino Y; Sugiyama Y; Namkoong H; Horita N; Yoshimi R; Nakajima H;
Front Immunol; 2021; 12():803410. PubMed ID: 34938300
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems.
Ma R; Wang Q; Meng D; Li K; Zhang Y
BMC Cancer; 2021 Jan; 21(1):38. PubMed ID: 33413213
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge.
Frascaro F; Bianchi N; Sanguettoli F; Marchini F; Meossi S; Zanarelli L; Tonet E; Serenelli M; Guardigli G; Campo G; Calabrò L; Pavasini R
J Clin Med; 2023 Dec; 12(24):. PubMed ID: 38137806
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.
Baik AH; Tsai KK; Oh DY; Aras MA
Clin Sci (Lond); 2021 Mar; 135(5):703-724. PubMed ID: 33686402
[TBL] [Abstract][Full Text] [Related]
10. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review.
Cozma A; Sporis ND; Lazar AL; Buruiana A; Ganea AM; Malinescu TV; Berechet BM; Fodor A; Sitar-Taut AV; Vlad VC; Negrean V; Orasan OH
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142866
[TBL] [Abstract][Full Text] [Related]
11. A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer.
Hu Y; Liu C; Jin S; Yi Z; Wang C; Pan X; Huang H
BMC Pulm Med; 2023 Apr; 23(1):119. PubMed ID: 37060029
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners.
Wojtukiewicz MZ; Rek MM; Karpowicz K; Górska M; Polityńska B; Wojtukiewicz AM; Moniuszko M; Radziwon P; Tucker SC; Honn KV
Cancer Metastasis Rev; 2021 Sep; 40(3):949-982. PubMed ID: 34236546
[TBL] [Abstract][Full Text] [Related]
13. Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program.
Naqash AR; Moey MYY; Cherie Tan XW; Laharwal M; Hill V; Moka N; Finnigan S; Murray J; Johnson DB; Moslehi JJ; Sharon E
J Clin Oncol; 2022 Oct; 40(29):3439-3452. PubMed ID: 35658474
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis.
Liu M; Cheng X; Ni R; Zheng B; Huang S; Yang J
Front Immunol; 2022; 13():1006860. PubMed ID: 36189211
[TBL] [Abstract][Full Text] [Related]
15. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
16. Drug therapy for myocarditis induced by immune checkpoint inhibitors.
Wu Y; Xu Y; Xu L
Front Pharmacol; 2023; 14():1161243. PubMed ID: 37305530
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of low-intensity pulsed ultrasound on immune checkpoint inhibitor-related myocarditis via fine-tuning CD4
Fu S; Guo Z; Xu X; Li Y; Choi S; Zhao P; Shen W; Gao F; Wang C; Chen S; Li Y; Tian J; Sun P
Cancer Immunol Immunother; 2024 Jan; 73(1):15. PubMed ID: 38236243
[TBL] [Abstract][Full Text] [Related]
18. Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.
Zhu H; Galdos FX; Lee D; Waliany S; Huang YV; Ryan J; Dang K; Neal JW; Wakelee HA; Reddy SA; Srinivas S; Lin LL; Witteles RM; Maecker HT; Davis MM; Nguyen PK; Wu SM
Circulation; 2022 Jul; 146(4):316-335. PubMed ID: 35762356
[TBL] [Abstract][Full Text] [Related]
19. Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review.
Lehmann LH; Cautela J; Palaskas N; Baik AH; Meijers WC; Allenbach Y; Alexandre J; Rassaf T; Müller OJ; Aras M; Asnani AH; Deswal A; Laufer-Perl M; Thuny F; Kerneis M; Hayek SS; Ederhy S; Salem JE; Moslehi JJ
JAMA Cardiol; 2021 Nov; 6(11):1329-1337. PubMed ID: 34232253
[TBL] [Abstract][Full Text] [Related]
20. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.
Poto R; Troiani T; Criscuolo G; Marone G; Ciardiello F; Tocchetti CG; Varricchi G
Front Immunol; 2022; 13():804597. PubMed ID: 35432346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]